VistaGen Therapeutics Inc

VistaGen Therapeutics Inc is a clinicalstage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety depression and various other disorders impacting the central nervous system CNS A key component of its CNS pipeline is PH94B a fastacting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder PH94B also shows potential for addressing a broader spectrum of anxiety conditions including adjustment disorder with anxiety postpartum anxiety posttraumatic stress disorder PTSD preprocedural anxiety and panic disorders The companys CNS development initiatives further encompass PH10 another quickacting neuroactive nasal spray which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder MDD Additionally VistaGen is developing AV101 an oral NmethylDaspartate receptor antagonist which is being investigated in conjunction with oral probenecid for its potential application in treating levodopainduced dyskinesia MDD neuropathic pain and suicidal ideation VistaGen has established various collaborations including a contract research and development agreement with Cato Research Ltd a licensing agreement with Pherin Pharmaceuticals Inc and a license and collaboration agreement with EverInsight Therapeutics Inc Founded in 1998 VistaGen Therapeutics Inc is headquartered in South San Francisco California